FONAR (NASDAQ:FONR) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for FONAR and Soleno Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
FONAR | 0 | 0 | 0 | 0 | N/A |
Soleno Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 687.88%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than FONAR.
Profitability
This table compares FONAR and Soleno Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
FONAR | 8.28% | 5.57% | 3.99% |
Soleno Therapeutics | N/A | -88.69% | -51.63% |
Insider & Institutional Ownership
62.1% of FONAR shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares FONAR and Soleno Therapeutics' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
FONAR | $85.69 million | 1.35 | $8.24 million | N/A | N/A |
Soleno Therapeutics | N/A | N/A | $-30,770,000.00 | ($0.70) | -1.57 |
FONAR has higher revenue and earnings than Soleno Therapeutics.
Volatility & Risk
FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Summary
FONAR beats Soleno Therapeutics on 8 of the 11 factors compared between the two stocks.